Effect of Mindfulness in Parkinso
Not Applicable
- Conditions
- Parkinson's disease.Parkinson disease
- Registration Number
- IRCT20181007041258N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Diagnosis of Parkinson's Disease based on the UK Brain Bank Criteria.
Patients with Hoen and Yahr degree of 1-3
Regular treatment of Parkinson's disease with related drugs
Exclusion Criteria
The need to adjust the dose of Parkinson's drug in the last three months (before entering the study)
Having an unstable or life-threatening illness
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PDQ39 index. Timepoint: before and 8 weeks after intervention. Method of measurement: PDQ39 standard questionnaire.
- Secondary Outcome Measures
Name Time Method PDQ39 index score. Timepoint: 8 weeks later. Method of measurement: Standard questionnaire.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does mindfulness therapy modulate in Parkinson's disease (PD) patients compared to dopaminergic treatments?
How does IRCT20181007041258N1 mindfulness intervention compare to standard-of-care like levodopa in improving PD quality of life metrics?
Which biomarkers (e.g., alpha-synuclein, dopamine transporter levels) predict response to mindfulness-based interventions in PD populations?
What are the safety profiles and adverse event management strategies for mindfulness therapy versus conventional PD pharmacotherapies?
What integrative approaches combine mindfulness with dopaminergic or MAO-B inhibitor therapies for PD treatment optimization?